Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Martha Lacy, S. R. Hayman, Morie Gertz, K. D. Short, Angela Dispenzieri, Shaji K Kumar, P. R. Greipp, J. A. Lust, Stephen J Russell, David M Dingli, S. Zeldenrust, Rafael Fonseca, Peter Leif Bergsagel, Vivek Roy, Joseph R Mikhael, Alexander Keith Stewart, K. Laumann, J. B. Allred, Sumithra J Mandrekar, S Vincent Rajkumar & 1 others F. Buadi

Research output: Contribution to journalArticle

159 Citations (Scopus)

Abstract

Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in this group, we treated a cohort of lenalidomide refractory patients. Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly. Responses were assessed by the International Myeloma Working Group Criteria. Thirty-four patients were enrolled. The best response was very good partial response in 3 (9%), partial response (PR) in 8 (23%), best responses (MR) in 5 (15%), stable disease in 12 (35%) and progressive disease in 6 (18%), for an overall response rate of 47%. Of the 14 patients that were considered high risk, 8 (57%) had responses including 4 PR and 4 MR. The median time to response was 2 months and response duration was 9.1 months, respectively. The median overall survival was 13.9 months. Toxicity was primarily hematologic, with grade 3 or 4 toxicity seen in 18 patients (53%) consisting of anemia (12%), thrombocytopenia (9%) and neutropenia (26%). The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma.

Original languageEnglish (US)
Pages (from-to)1934-1939
Number of pages6
JournalLeukemia
Volume24
Issue number11
DOIs
StatePublished - Nov 23 2010

Fingerprint

Multiple Myeloma
Dexamethasone
Neutropenia
Thrombocytopenia
pomalidomide
lenalidomide
Anemia
Survival
Therapeutics
Pharmaceutical Preparations

Keywords

  • clinical trial
  • immunomodulatory drugs
  • mulitiple myeloma
  • therapy

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

@article{f7f93e58c4da471b96aba52296b6ed00,
title = "Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)",
abstract = "Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in this group, we treated a cohort of lenalidomide refractory patients. Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly. Responses were assessed by the International Myeloma Working Group Criteria. Thirty-four patients were enrolled. The best response was very good partial response in 3 (9{\%}), partial response (PR) in 8 (23{\%}), best responses (MR) in 5 (15{\%}), stable disease in 12 (35{\%}) and progressive disease in 6 (18{\%}), for an overall response rate of 47{\%}. Of the 14 patients that were considered high risk, 8 (57{\%}) had responses including 4 PR and 4 MR. The median time to response was 2 months and response duration was 9.1 months, respectively. The median overall survival was 13.9 months. Toxicity was primarily hematologic, with grade 3 or 4 toxicity seen in 18 patients (53{\%}) consisting of anemia (12{\%}), thrombocytopenia (9{\%}) and neutropenia (26{\%}). The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma.",
keywords = "clinical trial, immunomodulatory drugs, mulitiple myeloma, therapy",
author = "Martha Lacy and Hayman, {S. R.} and Morie Gertz and Short, {K. D.} and Angela Dispenzieri and Kumar, {Shaji K} and Greipp, {P. R.} and Lust, {J. A.} and Russell, {Stephen J} and Dingli, {David M} and S. Zeldenrust and Rafael Fonseca and Bergsagel, {Peter Leif} and Vivek Roy and Mikhael, {Joseph R} and Stewart, {Alexander Keith} and K. Laumann and Allred, {J. B.} and Mandrekar, {Sumithra J} and Rajkumar, {S Vincent} and F. Buadi",
year = "2010",
month = "11",
day = "23",
doi = "10.1038/leu.2010.190",
language = "English (US)",
volume = "24",
pages = "1934--1939",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

AU - Lacy, Martha

AU - Hayman, S. R.

AU - Gertz, Morie

AU - Short, K. D.

AU - Dispenzieri, Angela

AU - Kumar, Shaji K

AU - Greipp, P. R.

AU - Lust, J. A.

AU - Russell, Stephen J

AU - Dingli, David M

AU - Zeldenrust, S.

AU - Fonseca, Rafael

AU - Bergsagel, Peter Leif

AU - Roy, Vivek

AU - Mikhael, Joseph R

AU - Stewart, Alexander Keith

AU - Laumann, K.

AU - Allred, J. B.

AU - Mandrekar, Sumithra J

AU - Rajkumar, S Vincent

AU - Buadi, F.

PY - 2010/11/23

Y1 - 2010/11/23

N2 - Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in this group, we treated a cohort of lenalidomide refractory patients. Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly. Responses were assessed by the International Myeloma Working Group Criteria. Thirty-four patients were enrolled. The best response was very good partial response in 3 (9%), partial response (PR) in 8 (23%), best responses (MR) in 5 (15%), stable disease in 12 (35%) and progressive disease in 6 (18%), for an overall response rate of 47%. Of the 14 patients that were considered high risk, 8 (57%) had responses including 4 PR and 4 MR. The median time to response was 2 months and response duration was 9.1 months, respectively. The median overall survival was 13.9 months. Toxicity was primarily hematologic, with grade 3 or 4 toxicity seen in 18 patients (53%) consisting of anemia (12%), thrombocytopenia (9%) and neutropenia (26%). The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma.

AB - Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in this group, we treated a cohort of lenalidomide refractory patients. Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly. Responses were assessed by the International Myeloma Working Group Criteria. Thirty-four patients were enrolled. The best response was very good partial response in 3 (9%), partial response (PR) in 8 (23%), best responses (MR) in 5 (15%), stable disease in 12 (35%) and progressive disease in 6 (18%), for an overall response rate of 47%. Of the 14 patients that were considered high risk, 8 (57%) had responses including 4 PR and 4 MR. The median time to response was 2 months and response duration was 9.1 months, respectively. The median overall survival was 13.9 months. Toxicity was primarily hematologic, with grade 3 or 4 toxicity seen in 18 patients (53%) consisting of anemia (12%), thrombocytopenia (9%) and neutropenia (26%). The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma.

KW - clinical trial

KW - immunomodulatory drugs

KW - mulitiple myeloma

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=78149468560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149468560&partnerID=8YFLogxK

U2 - 10.1038/leu.2010.190

DO - 10.1038/leu.2010.190

M3 - Article

VL - 24

SP - 1934

EP - 1939

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -